XM无法为美国居民提供服务。
A
A

Amgen


市场新闻

Amgen must face lawsuit claiming it hid $10.7 billion tax bill

UPDATE 1-Amgen must face lawsuit claiming it hid $10.7 billion tax bill Adds details from decision, case citation, byline By Jonathan Stempel NEW YORK, Sept 30 (Reuters) - A federal judge said Amgen AMGN.O must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion for underreporting six years of taxes.
A

Amgen must face lawsuit claiming it hid $10.7 billion tax bill

Amgen must face lawsuit claiming it hid $10.7 billion tax bill NEW YORK, Sept 30 (Reuters) - A federal judge said Amgen AMGN.O must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion in taxes and penalties. U.S. District Judge John Cronan in Manhattan ruled on Monday that shareholders plausibly alleged they were misled by Amgen's concealing the true extent of its potential liability, and that the om
A

U.S. stocks weekly: Streaking in September

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl
A
C
M
R
V
L
W
U
U

U.S. stocks weekly: Streaking in September

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ
A
C
M
R
V
L
W
U
U

Dow closes at record high as tame inflation report also lifts small caps

US STOCKS-Dow closes at record high as tame inflation report also lifts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 0.67% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up 0.33%, S&P 500 down 0.13%, Nasdaq down 0.39% Updates with 4:23 pm ET By Echo Wang Sept 27 (Reuters) - T he blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more Federal Reserve rat
A
A
C
C
N
N
U
U

Dow closes at record high on tame inflation report that also boosts small caps

US STOCKS-Dow closes at record high on tame inflation report that also boosts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 1.5% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up, S&P 500 down, Nasdaq down Updates to 4:00 PM ET By Echo Wang Sept 27 (Reuters) - The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued inflation report that also lifted small -cap
A
A
C
C
N
N
U
U

Dow hits record high on tame inflation report that also boosts small caps

US STOCKS-Dow hits record high on tame inflation report that also boosts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 1.5% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up 0.45%, S&P 500 down 0.06%, Nasdaq down 0.32% Updates to 2:21 p.m. By Echo Wang Sept 27 (Reuters) - The blue-chip Dow Jones Industrial Average hit a new record high on Friday as investors cheered a tame inflation report that also boosted smal
A
A
C
C
N
N
U
U

S&P 500, Dow close lower as investors await insights on Fed rates, data

US STOCKS-S&P 500, Dow close lower as investors await insights on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.70%, S&P 500 down 0.19%, Nasdaq up 0.04% Updates with closing prices By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 closed lower on Wednesday, pulling back from recent record highs driven by China's sweeping stimulus packa
A
A
C
N
U
U

S&P 500, Dow end lower as investors await clues on Fed rates, data

US STOCKS-S&P 500, Dow end lower as investors await clues on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Dow weighed down by decline Amgen Updates with closing details By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 closed lower on Wednesday, retreating from recent record highs fueled by China's sweeping stimulus package , as investors awaited further
A
A
C
N
U
U

Argenx tops BEL 20 index, broker points to positive Vyvgart momentum

BUZZ-Argenx tops BEL 20 index, broker points to positive Vyvgart momentum Updates with U.S. listed shares ** Shares of Belgian biotech company Argenx ARGX.BR closed 3.5 % higher at 485.10 euros, on Wednesday ** Stock topped Belgium's blue-chip BEL 20 index .BFX * * A nalysts at brokerage KBC Securities s ay c ompany's drug Vyvgart is still the top
A

S&P 500, Dow retreat as investors await clues on Fed rates, data

US STOCKS-S&P 500, Dow retreat as investors await clues on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.63%, S&P 500 down 0.18%, Nasdaq up 0.03% Updates prices, details throughout By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 edged lower on Wednesday, pulling back from recent record highs spurred by China's sweeping stimulus packa
A
A
C
N
U
U

U.S. STOCKS SLM Corp, Amgen Inc, Cintas Corp

BUZZ-U.S. STOCKS ON THE MOVE-SLM Corp, Amgen Inc, Cintas Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed on Wednesday, with the S&P 500 hovering near a record high, as investors awaited more indicators on the state of the economy and upcoming interest rate reductions.
A
A
A
C
C
H
M
N
S
F
U
U
G

Wall Street mixed as investors await Fed rate clues, data

US STOCKS-Wall Street mixed as investors await Fed rate clues, data For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.48%, S&P 500 flat, Nasdaq up 0.26% Updated at 11:42 a.m.
A
A
C
N
U
U

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +4.2% Intel Corp INTC.OQ +3.4% NVIDIA Corp NVDA.OQ +2.2% Arm Holdings PLC ARM.OQ +2.2% Advanced Micro Devices Inc AMD.OQ +2.0% Bottom Performers Percent Change Amgen Inc AMGN.OQ -4.7% Diamondback Energy Inc FANG.OQ -2.1% Charter Communications Inc CHTR.OQ -1.9% CoStar Group Inc CSGP.OQ -1.9% Dexcom Inc DXCM.OQ -1.7% The Nasdaq 100 .NDX gained 31.72
A
C
I
N
A
U
D
D
C

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Vistra Corp VST.N +6.8% Hewlett Packard Enterprise Co HPE.N +4.9% Constellation Energy Corp CEG.OQ +4.4% Intel Corp INTC.OQ +3.2% NVIDIA Corp NVDA.OQ +2.3% Bottom Performers Percent Change General Motors Co GM.N -5.4% Global Payments I
A
I
N
U
G

Amgen falls after reporting mixed data on two drugs

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the
A
R
S

Street View: Amgen's mixed data on two drugs fans competition concerns

BUZZ-Street View: Amgen's mixed data on two drugs fans competition concerns ** Amgen's AMGN.O drugs, Uplizna and rocatinlimab, for a rare muscular disorder and for a skin disease, respectively, met the main goals in their late-stage studies ** However, results from its drug rocatinlimab for treating atopic dermatitis or eczema, fell short of its co
A

ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum

BUZZ-ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum ** Shares in Belgian biotech company Argenx ARGX.BR rise 4%, with KBC analysts saying its Vyvgart drug is still the top contender despite positive trial data from a competitor ** Amgen AMGN.O on Tuesday reported favourable phase 3 data for its Uplizna drug in treating rare muscle-weakening disease myasthenia gravis ** "We deem the Uplizna dataset to be strong yet somewhat less compelling than Vyvgart," KBC says ** "Vyvgart
A

Amgen's muscular disorder drug meets main goal in late-stage study

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ
A
A
R
S

Amgen's experimental skin disease drug meets main goals in study

Amgen's experimental skin disease drug meets main goals in study Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for an inflammatory skin condition known as atopic dermatitis. Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by
A



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明